Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis: a systematic review and meta-analysis.

Lee SH, Chang SS, Lee M, Chan RC, Lee CC.

Osteoporos Int. 2014 Mar;25(3):1131-9. doi: 10.1007/s00198-013-2575-3. Epub 2013 Dec 17. Review.

PMID:
24343364
2.

Use of bisphosphonates and the risk of osteonecrosis among cancer patients: a systemic review and meta-analysis of the observational studies.

Lee SH, Chan RC, Chang SS, Tan YL, Chang KH, Lee MC, Chang HE, Lee CC.

Support Care Cancer. 2014 Feb;22(2):553-60. doi: 10.1007/s00520-013-2017-y. Epub 2013 Nov 8. Review.

PMID:
24203085
3.

Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures.

Lapi F, Cipriani F, Caputi AP, Corrao G, Vaccheri A, Sturkenboom MC, Di Bari M, Gregori D, Carle F, Staniscia T, Vestri A, Brandi M, Fusco V, Campisi G, Mazzaglia G; Bisphosphonates Efficacy-Safety Tradeoff (BEST) study group..

Osteoporos Int. 2013 Feb;24(2):697-705. doi: 10.1007/s00198-012-2013-y. Epub 2012 May 23.

PMID:
22618266
4.

Systematic literature review of bisphosphonates and osteonecrosis of the jaw in patients with osteoporosis.

Chamizo Carmona E, Gallego Flores A, Loza Santamaría E, Herrero Olea A, Rosario Lozano MP.

Reumatol Clin. 2013 May-Jun;9(3):172-7. doi: 10.1016/j.reuma.2012.05.005. Epub 2012 Jul 10. Review. English, Spanish.

5.
6.

A Large National Cohort Study of the Association between Bisphosphonates and Osteonecrosis of the Jaw in Patients with Osteoporosis: A Nested Case-control Study.

Kwon JW, Park EJ, Jung SY, Sohn HS, Ryu H, Suh HS.

J Dent Res. 2015 Sep;94(9 Suppl):212S-9S. doi: 10.1177/0022034515587862. Epub 2015 May 22. Erratum in: J Dent Res. 2016 Jan;95(1):121.

PMID:
26001708
7.

Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons.

Khan AA, Rios LP, Sándor GK, Khan N, Peters E, Rahman MO, Clokie CM, Dore E, Dubois S.

J Rheumatol. 2011 Jul;38(7):1396-402. doi: 10.3899/jrheum.100221. Epub 2011 Apr 15.

PMID:
21498483
8.

Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.

Khan AA, Sándor GK, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Dempster DW, Glorieux FH, Neville AJ, Talwar RM, Clokie CM, Al Mardini M, Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael RP, Blanas N, Kendler D, Petak S, St-Marie LG, Brown J, Evans AW, Rios L, Compston JE; Canadian Association of Oral and Maxillofacial Surgeons..

J Rheumatol. 2008 Jul;35(7):1391-7. Epub 2008 Jun 1. Erratum in: J Rheumatol. 2008 Oct;35(10):2084. J Rheumatol. 2008 Aug;35(8):1688.

PMID:
18528958
9.

Bisphosphonate associated osteonecrosis of the jaw.

Khan AA, Sándor GK, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Lentle B, Dempster DW, Glorieux FH, Neville AJ, Talwar RM, Clokie CM, Mardini MA, Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael RP, Blanas N, Kendler D, Petak S, Ste-Marie LG, Brown J, Evans AW, Rios L, Compston JE; Canadian Taskforce on Osteonecrosis of the Jaw..

J Rheumatol. 2009 Mar;36(3):478-90. doi: 10.3899/jrheum.080759. Review.

PMID:
19286860
10.

Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.

Otto S, Schreyer C, Hafner S, Mast G, Ehrenfeld M, Stürzenbaum S, Pautke C.

J Craniomaxillofac Surg. 2012 Jun;40(4):303-9. doi: 10.1016/j.jcms.2011.05.003. Epub 2011 Jun 14.

PMID:
21676622
11.

Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population.

Lin TC, Yang CY, Kao Yang YH, Lin SJ.

Osteoporos Int. 2014 May;25(5):1503-11. doi: 10.1007/s00198-014-2624-6. Epub 2014 Feb 11.

PMID:
24515577
12.

Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study.

Wessel JH, Dodson TB, Zavras AI.

J Oral Maxillofac Surg. 2008 Apr;66(4):625-31. doi: 10.1016/j.joms.2007.11.032.

13.

Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges.

Solomon DH, Mercer E, Woo SB, Avorn J, Schneeweiss S, Treister N.

Osteoporos Int. 2013 Jan;24(1):237-44. doi: 10.1007/s00198-012-2042-6. Epub 2012 Jun 16. Review.

PMID:
22707065
14.

Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis.

Tennis P, Rothman KJ, Bohn RL, Tan H, Zavras A, Laskarides C, Calingaert B, Anthony MS.

Pharmacoepidemiol Drug Saf. 2012 Aug;21(8):810-7. doi: 10.1002/pds.3292. Epub 2012 Jun 19.

PMID:
22711458
15.

Antiresorptives and osteonecrosis of the jaw.

Yamashita J, McCauley LK.

J Evid Based Dent Pract. 2012 Sep;12(3 Suppl):233-47. doi: 10.1016/S1532-3382(12)70046-5. Review.

PMID:
23040351
16.

Bisphosphonates for breast cancer.

Pavlakis N, Schmidt R, Stockler M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD003474.

PMID:
16034900
18.

Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies.

Sun K, Liu JM, Sun HX, Lu N, Ning G.

Osteoporos Int. 2013 Jan;24(1):279-86. doi: 10.1007/s00198-012-2158-8. Epub 2012 Oct 6.

PMID:
23052941
19.

Bisphosphonates and atrial fibrillation: systematic review and meta-analysis.

Loke YK, Jeevanantham V, Singh S.

Drug Saf. 2009;32(3):219-28. doi: 10.2165/00002018-200932030-00004. Review.

PMID:
19338379
20.

Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database.

de Boissieu P, Kanagaratnam L, Abou Taam M, Roux MP, Dramé M, Trenque T.

Pharmacoepidemiol Drug Saf. 2014 Sep;23(9):989-92. doi: 10.1002/pds.3622. Epub 2014 Apr 15.

PMID:
24737486

Supplemental Content

Support Center